SLT is the sensible option

Article

Selective laser trabeculoplasty (SLT) should be used before alteration of treatment or trabeculectomy, according to the findings of a study conducted by Bharat Kapoor and a team of colleagues from the UK.

Selective laser trabeculoplasty (SLT) should be used before alteration of treatment or trabeculectomy, according to the findings of a study conducted by Bharat Kapoor and a team of colleagues from the UK.

The team conducted a retrospective analysis of case notes in order to evaluate the success rate, duration of success and the factors that influence the outcome of SLT in patients with open angle glaucoma and ocular hypertension (OHT) uncontrolled on maximum tolerated medical treatment (MTMT). A total of 88 case notes (155 eyes) were reviewed with success being defined as a reduction in intraocular pressure (IOP) of 20% from baseline. Patients showing no response up to three months following treatment were classified as non-responders.

The average number of topical medication drops per patient prior to SLT was 1.86. A total of 92% of eyes responded to SLT treatment and, of these, 88% achieved target IOP by month 12. Target IOP was reached by 69% at two years, 36.8% at three years, 20.8% at four years and 18% at five years. Those patients using prostaglandin analogues prior to SLT demonstrated an average duration of success of 29 months compared with 31 months for patients not using the analogues. A significant number of patients were able to stop using eye drops following the treatment.

Kapoor and colleagues recommended that SLT should be used before alteration of treatment or trabeculectomy. It is able to omit patient compliance factor whilst also reducing the cost burden of additional topical medication. In addition to these factors, it is also a repeatable procedure since it does not damage the trabecular meshwork.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.